BCTX Stock Summary and Trading Ideas (Briacell Therapeutics Corp. - Common Shares | NASDAQ:BCTX)

BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.

Briacell Therapeutics Corp. - Common Shares trades on the NASDAQ stock market under the symbol BCTX.

As of September 21, 2026, BCTX stock price declined to $4.15 with 164,898 million shares trading.

BCTX has a beta of 2.29, meaning it tends to be more sensitive to market movements. BCTX has a correlation of 0.08 to the broad based SPY ETF.

BCTX has a market cap of $36.10 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, BCTX traded as high as $954.00 and as low as $2.60.

BCTX has underperformed the market in the last year with a return of -54.3%, while SPY returned +18.5%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in BCTX shares. However, BCTX has outperformed the market in the last 3 month and 2 week periods, returning +43.1% and +16.2%, while SPY returned +3.8% and +0.7%, respectively. This indicates BCTX has been having a stronger performance recently.

BCTX support price is $3.96 and resistance is $4.46 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BCTX shares will trade within this expected range on the day.